Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KIO 301

Next Previous
Drug Profile

KIO 301

Alternative Names: B-203; BENAQ; KIO-301

Latest Information Update: 22 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayon Therapeutics
  • Developer Kiora Pharmaceuticals
  • Class Amides; Aniline compounds; Aza compounds; Eye disorder therapies; Small molecules
  • Mechanism of Action Hyperpolarisation activated cation channel antagonists; Voltage-gated potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Choroideraemia; Stargardt disease; Retinitis pigmentosa; Usher syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Choroideraemia; Retinitis pigmentosa; Stargardt disease

Most Recent Events

  • 22 Sep 2025 Phase-II clinical trials in Retinitis pigmentosa in Australia (Intravitreous) (NCT06628947)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Retinitis-pigmentosa in USA (Intravitreous, Injection)
  • 04 Sep 2024 Phase-II clinical trials in Choroideraemia (Intravitreous) prior to September 2024 (Kiora Pharmaceuticals pipeline, September 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top